Invex Targets Multiple Sclerosis Drug With Rekover Deal And $10 Million Raise
Invex has agreed to acquire all of New Zealand biotech Rekover, adding its experimental nalfurafine treatment for multiple-sclerosis-related optic nerve damage and a planned Phase 2a study; the deal is conditional on shareholder approval. The acquisition consideration is shares and milestone-based rights, with no cash payment, while Invex is seeking to raise $10 million to fund the study and continue developing its existing Exenatide assets.
Closing price · 2026-10-26: $0.120 · +14.29%